Anacor submits nail fungus drug NDA to FDA
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals' got a 2.5% boost in morning trading on 29 July on word the biotech had submitted its new drug application (NDA) to the US FDA for tavaborole, an experimental topical treatment for onychomycosis, a fungal infection of the nail and nail bed that affects about 35 million Americans.